A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Public ClinicalTrials.gov record NCT06123338. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Single-Arm, Multicenter Phase 2 Study of Neoadjuvant Pembrolizumab With Trastuzumab and Chemotherapy in Resectable HER2+ Esophagogastric Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
Study identification
- NCT ID
- NCT06123338
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 49 participants
Conditions and interventions
Interventions
- Pembrolizumab Drug
- Trastuzumab Drug
- Oxaliplatin Drug
- Capecitabine Drug
- 5-Fluorouracil Drug
- Docetaxel Drug
- Nutrition questionnaires (optional) Other
- stool and saliva samples (optional) Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2024
- Primary completion
- Nov 29, 2027
- Completion
- Nov 29, 2027
- Last update posted
- Jul 6, 2026
2024 – 2027
United States locations
- U.S. sites
- 10
- U.S. states
- 5
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Massachusetts General Hospital (Data Collection Only) | Boston | Massachusetts | 02114 | Recruiting |
| Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge | New Jersey | 07920 | Recruiting |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown | New Jersey | 07748 | Recruiting |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | New Jersey | 07645 | Recruiting |
| Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) | Commack | New York | 11725 | Recruiting |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | New York | 10604 | Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York | New York | 10065 | Recruiting |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale | New York | 11553 | Recruiting |
| University of Pennsylvania (Data Collection Only) | Philadelphia | Pennsylvania | 19104 | Recruiting |
| MD Anderson Cancer Center (Data Collection Only) | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06123338, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 6, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06123338 live on ClinicalTrials.gov.